Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of sulfonylanilines, featuring a piperidine core substituted with both a hydroxyaminocarbonyl group and a sulfonamide-linked butynylaniline moiety. It is listed as an experimental pharmaceutical in chemical databases and has been referenced in research contexts, but there are no indications of clinical use or advanced development. Its structure suggests potential utility as an inhibitor of matrix metalloproteinases (MMPs), particularly MMP13 (collagenase 3), MMP14, and MMP2, based on related chemical annotations. However, no detailed mechanism of action or therapeutic indication has been established in public sources[3][2][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tert-butyl 4-({[4-(but-2-yn-1-ylamino)phenyl]sulfonyl}methyl)-4-[(hydroxyamino)carbonyl]piperidine-1-carboxylate.